Search results for "Pyrimidine"
showing 9 items of 589 documents
Poly[[tetramethanolbis[4-oxo-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-olato]disodium]–diethyl ether–metha…
2016
In the title compound, [Na2(C16H7Cl3N5O2)2(CH3OH)4]·C4H10O·2CH3OH, the central pyrazolo[3,4-d]pyrimidine system makes dihedral angles of 82.98 (7)° with the trichlorophenyl ring and 13.11 (15)° with the pyridine ring. The sodium ion has an octahedral environment, being coordinated by four methanol molecules and one O and one N atom of two different heterocyclic ring systems.
Fighting Antibiotic Resistance: New Pyrimidine-Clubbed Benzimidazole Derivatives as Potential DHFR Inhibitors
2023
The present work describes the design and development of seventeen pyrimidine-clubbed benzimidazole derivatives as potential dihydrofolate reductase (DHFR) inhibitors. These compounds were filtered by using ADMET, drug-likeness characteristics calculations, and molecular docking experiments. Compounds 27, 29, 30, 33, 37, 38, and 41 were chosen for the synthesis based on the results of the in silico screening. Each of the synthesized compounds was tested for its in vitro antibacterial and antifungal activities using a variety of strains. All the compounds showed antibacterial properties against Gram-positive bacteria (Staphylococcus aureus and Staphylococcus pyogenes) as well as Gram-negativ…
Synthesis and Antitumor Evaluation of Menthone-Derived Pyrimidine-Urea Compounds as Potential PI3K/Akt/mTOR Signaling Pathway Inhibitor.
2022
A series of novel menthone derivatives bearing pyrimidine and urea moieties was designed and synthesized to explore more potent natural product-derived antitumor agents. The structures of the target compounds were confirmed by FTIR, NMR, and HRMS. The in vitro antitumor activity was tested by standard methyl thiazolytetrazolium assay and showed that 4i, 4g, 4s, and 4m are the best compounds with IC50 values of 6.04 ± 0.62µM, 3.21 ± 0.67µM, 19.09 ± 0.49µM, and 18.68 ± 1.53µM, against Hela, MGC-803, MCF-7, and A549, respectively. The results of the preliminary action mechanism studies showed that compound 4i, the representative compound, could induce cell apoptosis in Hela cells in a dose-dep…
CCDC 238750: Experimental Crystal Structure Determination
2005
Related Article: M.Ruben, U.Ziener, J.-M.Lehn, V.Ksenofontov, P.Gutlich, G.B.M.Vaughan|2005|Chem.-Eur.J.|11|94|doi:10.1002/chem.200400584
CCDC 150832: Experimental Crystal Structure Determination
2001
Related Article: E.Breuning, U.Ziener, J.-M.Lehn, E.Wegelius, K.Rissanen|2001|Eur.J.Inorg.Chem.||1515|doi:10.1002/1099-0682(200106)2001:6<1515::AID-EJIC1515>3.0.CO;2-T
CCDC 256886: Experimental Crystal Structure Determination
2005
Related Article: L.H.Uppadine, J.-P.Gisselbrecht, N.Kyritsakas, K.Nattinen, K.Rissanen, J.-M.Lehn|2005|Chem.-Eur.J.|11|2549|doi:10.1002/chem.200401224
CCDC 173965: Experimental Crystal Structure Determination
2003
Related Article: G.Marinescu, R.Lecouezec, D.Armentano, G.De Munno, M.Andruh, S.Uriel, R.Llusar, F.Lloret, M.Julve|2002|Inorg.Chim.Acta|336|46|doi:10.1016/S0020-1693(02)00880-0
MTOR inhibitor-based combination therapies for pancreatic cancer
2018
Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification. Methods: We used Mtor floxed mice to analyse the function of the kinase in context of the pancreas at the genetic level. Using a dual-recombinase system, which is based on the flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies, we generated a novel cellular model, allowing the genetic analysis of MTOR functions in tumour maintenance. Cross-species validation and pha…
CCDC 725442: Experimental Crystal Structure Determination
2010
Related Article: E.Colacio, H.Aouryaghal, A.J.Mota, J.Cano, R.Sillanpaa, A.Rodriguez-Dieguez|2009|CrystEngComm|11|2054|doi:10.1039/b906382j